Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4180.50 +0.2% SILVER 57.10 −0.1% COPPER 6.56 −0.0% OIL 98.97 +1.0% PALLADIUM 1113.00 −1.4% MSV 0.570 +0.0% CCMM 0.500 +3.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.520 +0.0% FMR 0.225 +0.0% GSVR 0.345 +1.5% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.060 +0.0% GOLD 4180.50 +0.2% SILVER 57.10 −0.1% COPPER 6.56 −0.0% OIL 98.97 +1.0% PALLADIUM 1113.00 −1.4% MSV 0.570 +0.0% CCMM 0.500 +3.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.520 +0.0% FMR 0.225 +0.0% GSVR 0.345 +1.5% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.060 +0.0%
Earnings

Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update

By The Northwire Desk — AI Analysis Nov 17, 2025 · 07:00 LOVE · 1.62 Cannara Biotech Inc.
LOVE · Price

Executive Summary

  • Cannara Biotech announced that its fiscal Q4 and full‑year 2025 financial results will be released on Monday, Nov 24 2025 at 7:00 a.m. ET.
  • CEO Zohar Krivorot and CFO Nicholas Sosiak will host an earnings webcast at 11:00 a.m. ET on the same day, with a live Q&A session.
  • The company announced the passing of long‑time board member Jack M. Kay, highlighting his extensive leadership background and expressing condolences to his family.

Key Details

  • Earnings Release Timing: Fiscal fourth quarter and fiscal year ended August 31 2025 results to be released 7:00 a.m. ET, Nov 24 2025.
  • Webcast Information: Hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak at 11:00 a.m. ET; registration link provided; archived after the event.
  • Investor Interaction: Investors may submit questions in advance to [email protected]; live questions accepted, with priority to emailed submissions.
  • Board Update – Passing of Jack M. Kay:
  • Board member since 2019; over five decades of pharmaceutical and sales executive experience.
  • Former CEO, COO, President, Vice Chairman of Apotex Inc.; held senior roles at Helix Biopharma Corp., Cangene Corp., Barr Pharmaceuticals Inc.
  • Community leadership includes Chairmanship of Humber River Regional Hospital (Toronto).
  • Company extends condolences to his family and thanks him for his service.

Notable Quotes

No direct quotes were included in the release.

Read the original news release →

More from Cannara Biotech Inc.

May 06, 2026 · 08:00

Cannara Consolidates Quebec Operations

M&A / Property Apr 14, 2026 · 07:00

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

Earnings Apr 07, 2026 · 07:00

Cannara Biotech Inc.

Earnings Feb 26, 2026 · 08:00

Cannara Announces Graduation to the Toronto Stock Exchange

Regulatory Feb 04, 2026 · 17:47

Cannara Biotech closes $6.3-million private placement

Financings Feb 04, 2026 · 08:00

Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share

Financings